CSL has agreed to a partnership with Swiss drugmaker Alentis Therapeutics worth up to $1.6 billion to co-develop and co-promote lixudebart, an experimental treatment for rare kidney and liver diseases. CSL will pay $355 million upfront, with Alentis eligible for $1.2 billion in milestones. While CSL shares rose 1.3% on the news, analysts suggest the deal may not fully resolve long-term growth concerns following recent job cuts and vaccine spin-off delays.
Details of the CSL-Alentis deal
- ▪CSL entered into an agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases in a deal worth up to $1.6 billion.
- ▪CSL's partnership with Alentis Therapeutics is part of strategic initiatives launched in August 2025 to build its drug pipeline through external innovation.
- ▪Once lixudebart is commercialized, global profits from the drug will be shared with 55% going to CSL and 45% going to Alentis Therapeutics.
- ▪Under the agreement, CSL will make an upfront payment of $355 million to Alentis Therapeutics, while Alentis Therapeutics is eligible for up to $1.2 billion in commercial milestone payments.
Development and trials of lixudebart
- ▪Under the agreement, CSL will fully fund the RENAL trial through completion, a planned Phase 3 study for AAV-RPGN, and mid-stage development for other indications.
- ▪Lixudebart is being evaluated for anti-neutrophil cytoplasmic antibodies-associated vasculitis with rapidly progressive glomerulonephritis, focal segmental glomerulosclerosis, and primary sclerosing cholangitis.
- ▪The partnership focuses on lixudebart, an investigational claudin-1-targeting antibody being studied for rare, progressive autoimmune kidney and liver diseases.
- ▪Lixudebart is currently being evaluated in the Phase 2 RENAL trial for a rare autoimmune kidney disease that can cause irreversible kidney damage.
Pulmonary disease exclusion
- ▪The US Food and Drug Administration awarded lixudebart orphan drug designation for idiopathic pulmonary fibrosis in May 2024, an indication excluded from the CSL deal.
- ▪CSL excluded idiopathic pulmonary fibrosis from its partnership with Alentis Therapeutics because pulmonary diseases do not align with CSL's therapeutic areas.
Market reaction and CSL's outlook
- ▪Capital.com analyst Kyle Rodda stated that while the Alentis Therapeutics deal creates upside risks to future earnings, it is likely not enough to improve CSL's long-term growth outlook.
- ▪Following the deal announcement, CSL shares rose as much as 1.3% to A$177.550 on October 5, 2026, while the broader benchmark ASX 200 index rose 0.6%.
- ▪CSL has faced investor pressure due to plans to cut up to 3,000 jobs, downgraded earnings guidance, and delays in spinning off its Seqirus vaccines business.
Debatable claims
- ▪The FDA's orphan drug designation is an effective way to incentivize rare disease treatments
- ▪Prioritizing rare disease treatments is a more viable strategy for biotech firms than pursuing mass-market therapies
Story comments
Loading comments…